Program
hyaluronidase (human recombinant)
Also written as “Efgartigimod PH20 SC”, “efgartigimod PH20 SC” and “rHuPH20”.
Its studies are mostly in Diabetes Mellitus, Type 1 · Myasthenia Gravis · Primary Immunodeficiency Diseases · Dehydration · Multiple Myeloma, led by 7 companies.
Drug pageHyaluronidase (human recombinant): every studyMany companies study it; this page follows only the 57 they lead. All 69 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| argenx | 2211 open or running | phase 4since Oct 7, 2024 | Feb 20, 2020 | Mar 2027phase 2 · NCT06655155 |
| Halozyme Therapeuticsits history only | 200 open or running | phase 4since Apr 4, 2006 | Apr 4, 2006 | none ahead |
| Takedaits history only | 60 open or running | phase 3since Dec 23, 2008 | Oct 29, 2008 | none ahead |
| Hoffmann-La Rocheits history only | 42 open or running | phase 2since Sep 11, 2017 | Sep 11, 2017 | Aug 31, 2029phase 2 · NCT07503340 |
| Baxter Healthcareits history only | 30 open or running | phase 4since Dec 10, 2008 | Dec 10, 2008 | none ahead |
| Fosun Pharmaits history only | 11 open or running | phase 1since Feb 24, 2026 | Feb 24, 2026 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 1since Aug 6, 2015 | Aug 6, 2015 | none ahead |
Also a collaborator on its studies: BioLineRx.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of argenx only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 8 studies since Feb 20, 2020.
- Feb 14, 2022Phase 3 study in Pemphigoid, BullousNCT05267600 · 98 enrolled · United States, Australia, Bulgaria and more
- Dec 8, 2022Phase 3 study in Pemphigoid, BullousNCT05681481 · 64 enrolled · United States, Australia, Bulgaria and more
- Jul 28, 2023Phase 3 study in MyositisNCT05979441 · 240 planned · United States, Argentina, Austria and more
- Mar 6, 20242 phase 3 studies in Graves OphthalmopathyNCT06307626, NCT06307613
- Apr 26, 2024Phase 3 study in Myasthenia GravisNCT06392386 · 12 planned · United States, Australia, Belgium and more
- Aug 14, 2024Phase 3 study in Myasthenia GravisNCT06558279 · 141 enrolled · United States, Australia, Austria and more
- Oct 7, 2024Phase 4 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06637072 · 23 enrolled · United States
- Oct 22, 2024Phase 2 study in Scleroderma, SystemicNCT06655155 · 87 enrolled · United States, Argentina, Belgium and more
- Nov 10, 2024Phase 3 study in Primary Sjogrens DiseaseNCT06684847 · 631 enrolled · United States, Argentina, Australia and more
- Mar 27, 2025Phase 4 study in New Onset Generalized Myasthenia Gravis (gMG)NCT06909214 · 30 planned · United States
- Apr 30, 2026Phase 3 study in Graves DiseaseNCT07570316 · 230 planned · United States, Georgia, United Kingdom
- May 13, 2026Phase 3 study in Graves DiseaseNCT07596849 · 230 planned · Belgium, Bulgaria, Canada and more
- Jul 29, 2026Phase 2 study in Sjogrens DiseaseNCT07760818 · 75 planned
- Oct 19, 2026Primary completion moved from 2026-10-01 to 2027-10Date moved laterphase 3 · +12 months · NCT04812925
Ahead
- Mar 2027Primary completion: phase 2 study in Scleroderma, SystemicNCT06655155
- Apr 30, 2027Primary completion: phase 2 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT04280718
- Jul 2027Primary completion: phase 3 study in Primary Sjogrens DiseaseNCT06684847
- Sep 2027Primary completion: phase 3 study in Myasthenia GravisNCT06392386
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 22 argenx leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07760818Sjogrens Disease | 2 | Not yet recruiting | Jul 28, 2028 | 75 |
| NCT07596849Graves Disease · Belgium, Bulgaria, Canada and more | 3 | Recruiting | Jun 2028 | 230 |
| NCT07570316Graves Disease · United States, Georgia, United Kingdom | 3 | Recruiting | Jun 2028 | 230 |
| NCT06909214New Onset Generalized Myasthenia Gravis (gMG) · United States | 4 | Recruiting | Aug 2026 | 30 |
| NCT06684847Primary Sjogrens Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jul 2027 | 631 |
| NCT06655155Scleroderma, Systemic · United States, Argentina, Belgium and more | 2 | Active, not recruiting | Mar 2027 | 87 |
| NCT06637072Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States | 4 | Completed | Feb 19, 2026 | 23 |
| NCT06558279Myasthenia Gravis · United States, Australia, Austria and more | 3 | Active, not recruiting | Jan 12, 2026 | 141 |
| NCT06392386Myasthenia Gravis · United States, Australia, Belgium and more | 3 | Recruiting | Sep 2027 | 12 |
| NCT06307626Graves Ophthalmopathy · United States, Austria, Bulgaria and more | 3 | Terminated | Dec 15, 2025 | 105 |
| NCT06307613Graves Ophthalmopathy · United States, Australia, Belgium and more | 3 | Terminated | Dec 15, 2025 | 102 |
| NCT05979441Myositis · United States, Argentina, Austria and more | 3 | By invitation | Sep 2028 | 240 |
| NCT05681481Pemphigoid, Bullous · United States, Australia, Bulgaria and more | 3 | Terminated | Mar 20, 2025 | 64 |
| NCT05267600Pemphigoid, Bullous · United States, Australia, Bulgaria and more | 3 | Completed | Sep 13, 2024 | 98 |
| NCT04812925Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 2027 | 173 |
| NCT04818671Myasthenia Gravis · United States, Belgium, Czechia and more | 3 | Completed | Dec 31, 2024 | 184 |
| NCT04735432Myasthenia Gravis · United States, Belgium, Georgia and more | 3 | Completed | Nov 2, 2021 | 110 |
| NCT04687072Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more | 3 | Completed | Oct 9, 2023 | 207 |
| NCT04598477Pemphigus · United States, Australia, Bulgaria and more | 3 | Terminated | Mar 25, 2024 | 183 |
| NCT04598451Pemphigus · United States, Australia, Bulgaria and more | 3 | Completed | Aug 22, 2023 | 222 |
| NCT04564066Healthy Volunteers · Netherlands | 1 | Completed | Dec 24, 2020 | 54 |
| NCT04280718Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Austria, Belgium and more | 2 | Active, not recruiting | Apr 30, 2027 | 229 |
How it is read
Names in the registry
- “Efgartigimod PH20 SC”, 12 entries
- “efgartigimod PH20 SC”, 10 entries
- “rHuPH20”, 5 entries
- “Recombinant human hyaluronidase PH20 (rHuPH20)”, 4 entries
- “recombinant human hyaluronidase”, 3 entries
Codes read as this program: RHUPH20.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 1, 6 studies
- Myasthenia Gravis, 5 studies
- Primary Immunodeficiency Diseases, 4 studies
- Dehydration, 4 studies
- Multiple Myeloma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.